Product class: Authorized package
Medicinal product class: Veterinary medicine
Package code: 1785843
Name of medicinal product: Animeloxan
Active substances:
Estonian, English, Latin
ATC code: QM01AC06
Dosage form: solution for injection
Route of administration: intravenous use; intramuscular use; subcutaneous use
Strengh: 20mg 1ml
Amount in package: 50ml 1TK
Legal status for supply*: Subject to medicinal prescription
Class of active substance:  
Additional information:  
Indication: Cattle: For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy. For the relief of post-operative pain following dehorning in calves. Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy Horses: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. For the relief of pain associated with equine colic.
Safety features: No
Summary of product characteristics (SPC):  (last updated 24 July 2023)
Package information leaflet (PIL): EST  (last updated 24 July 2023)
Labelling:  (last updated 24 September 2019)
Withdrawal time: Veis: Lihale ja söödavatele kudedele: 15 päeva Piimale: 5 päeva Siga: Lihale ja söödavatele kudedele: 8 päeva Hobune: Lihale ja söödavatele kudedele: 5 päeva Ei ole lubatud kasutamiseks hobustel, kelle piima tarvitatakse inimtoiduks.
Species: veis, hobune, siga
Last imported to Estonia: Never imported to Estonia
Marketing authorization holder: aniMedica GmbH 
Marketing authorization number: 2199 
Marketing authorization issued on: 24 September 2019 
Marketing authorization expires on: 24 September 2024 
Marketing authorization procedure type: Mutual recognition 
Entry/Changing date: 24 July 2023
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription